Cabaletta Bio, Inc. — FY2021 Form 10-K Summary
Business context and reporting period
This filing is an Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed March 17, 2022; it is not a standalone Q4 filing. Cabaletta Bio is a clinical-stage biotechnology company developing engineered CAAR T-cell therapies intended to selectively eliminate disease-causing B cells in autoimmune and alloimmune diseases.
- Lead program: DSG3-CAART for mucosal pemphigus vulgaris, evaluated in the Phase 1 DesCAARTes trial.
- Additional programs: MuSK-CAART for MuSK myasthenia gravis, DSG3/1-CAART, PLA2R-CAART, FVIII-CAART and two undisclosed discovery-stage targets.
- No product candidates had received regulatory approval, and the company had not generated product revenue.
- The company relies substantially on the University of Pennsylvania and affiliated entities for research, manufacturing and technology access.
Financial performance and key metrics
| Metric | FY2021 | FY2020 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $32.5 million | $21.4 million | +$11.1 million |
| General and administrative expense | $13.8 million | $12.5 million | +$1.4 million |
| Total operating expenses | $46.3 million | $33.8 million | +$12.5 million |
| Net loss | $46.3 million | $33.3 million | +$13.0 million loss |
| Net loss per share | $1.80 | $1.44 | Loss increased |
| Cash used in operating activities | $34.1 million | $26.8 million | +$7.3 million use |
| Cash and cash equivalents at year-end | $122.2 million | $101.4 million | +$20.8 million |
| Accumulated deficit | $112.6 million | $66.3 million | +$46.3 million |
| Total debt | No debt or credit facility disclosed | No debt or credit facility disclosed | Not applicable |
- R&D represented approximately 70% of total operating expenses. The filing does not present a meaningful gross or operating margin because the company had no revenue.
- R&D increases were driven primarily by development services, personnel, manufacturing and clinical-trial costs.
- Stock-based compensation was $5.8 million in 2021 versus $4.4 million in 2020.
- Year-end total assets were $126.3 million and stockholders’ equity was $118.0 million. Current liabilities were $8.4 million.
- Investing activities provided $6.0 million, primarily from investment maturities, partially offset by $1.2 million of property and equipment purchases.
- Financing activities provided $48.9 million, including $48.3 million of net proceeds from at-the-market common-stock sales and $0.6 million from option exercises and the employee stock purchase plan.
Material changes versus the prior comparable period
- Net loss increased 39% to $46.3 million, while total operating expenses increased 37% to $46.3 million.
- R&D expense increased 52%, reflecting greater clinical, manufacturing, outsourced development and staffing activity.
- The company sold 4.8 million shares under its ATM program in 2021, increasing shares outstanding to 28.9 million at December 31, 2021 and diluting existing holders.
- Cash increased by $20.8 million despite a $34.1 million operating cash burn because of equity financing and investment maturities.
- Manufacturing infrastructure expanded through collaborations with WuXi Advanced Therapies for cell processing and Oxford Biomedica for lentiviral-vector supply.
- The DesCAARTes trial produced no dose-limiting toxicities or clinically relevant adverse events in the first three cohorts reported in 2021, but the two lowest-dose cohorts showed no clear evidence of biologic activity.
- MuSK-CAART’s IND was submitted in Q4 2021 and became effective in January 2022. The filing also reports subsequent February 2022 fast-track designation.
- A CRO supporting data management, biostatistics and pharmacovigilance for DesCAARTes terminated for convenience in October 2021; the company transitioned to a new provider in December 2021.
Guidance, outlook, commentary, risks and unusual items
- Management expected year-end cash, cash equivalents and investments to fund operations through the third quarter of 2023, subject to assumptions that may prove incorrect. Additional financing is expected to be required.
- Near-term priorities include advancing DesCAARTes, initiating the planned MusCAARTes Phase 1 trial in 2022, continuing preclinical programs and developing commercial-grade manufacturing capabilities.
- The company expects significant additional losses and increasing R&D and general and administrative expenses for the foreseeable future. Profitability and product revenue are not expected for several years, if at all.
- Key execution risks include limited clinical experience, small and open-label early-stage trials, uncertain efficacy, potential cytokine release syndrome or other toxicities, patient enrollment, manufacturing comparability and supply constraints.
- Dependence on Penn is material. Penn’s manufacturing capacity, technology-transfer obligations and service agreements have termination rights and may not support late-stage or commercial supply.
- The CAAR T programs depend on in-licensed intellectual property. The Penn license includes approximately $21.0 million of potential aggregate milestone payments, low-single-digit royalties on net sales and potential sublicense-income sharing.
- The Oxford Biomedica agreement requires upfront and initial manufacturing payments of up to approximately $4.0 million, with potential milestones in the low tens of millions and low-single-digit royalties. Approximately $1.1 million was expensed in 2021.
- COVID-19 could delay clinical enrollment, manufacturing, supply, site operations and regulatory activities.
- On February 28, 2022, a purported stockholder filed a securities class-action complaint alleging misleading statements and omissions regarding the DesCAARTes trial and DSG3-CAART. The company intends to defend the matter; its outcome and potential financial impact were not estimable.
- Management assessed disclosure controls and internal control over financial reporting as effective as of December 31, 2021. The independent auditor did not provide an internal-control attestation because of the company’s emerging-growth-company exemption.
Most important facts for an investor to verify
- Whether higher-dose DesCAARTes cohorts demonstrate meaningful biologic activity, clinical benefit and durable safety after the disappointing low-dose results.
- The actual cash runway as clinical, manufacturing and infrastructure costs increase, and the timing and terms of future equity or other financing.
- Potential dilution from additional ATM sales, equity incentives and conversion of non-voting common stock.
- Whether Penn, WuXi, Oxford Biomedica and other suppliers can provide scalable, comparable and regulatory-compliant manufacturing capacity.
- The effectiveness and timing of the planned MuSK-CAART trial and the regulatory path for PLA2R-CAART and other preclinical programs.
- The scope, status and potential exposure associated with the securities class-action lawsuit filed in February 2022.
- Whether the company’s in-licensed patent portfolio remains valid, enforceable and sufficient to protect its CAAR T programs.